海外av无码网址入口_日韩亚洲中字在线_销魂老女人老熟妇69xx_被闺蜜玩sm(女绑女)_无码国产片观看_亚洲伦理在线电影_少妇免费一级黄片_影音先锋国产区免费观看_中文字幕精品人妻一区二区_黄品汇视频app污下载

 

 

 

Among them, on February 14th, Anbiping disclosed a reception and research announcement, and the company received 92 institutions including Minsheng Securities, Changsheng Fund, Boyuan Fund, Fenglan Investment, and Boshi Fund for research on February 12th. The company mentioned that its layout plan in the AI field can be roughly divided into three directions: first, internal empowerment, such as using AI technology to improve the efficiency of IHC antibody quality inspection; The second is product empowerment, including equipment intelligence and reagent diagnosis intelligence. In addition to the cervical cytology AI products and cytology assembly lines currently being developed, the company is also exploring the development of AI assisted products using immunohistochemistry and fluorescence in situ hybridization platforms. At the same time, the company is also collaborating with relevant pharmaceutical companies to implement AI applications; The third is the exploration of big model technology, especially multimodal big models. Currently, the core work is to standardize the annotation of pathological data and construct specialized big models.

 

 

 

On February 12th, Berry Gene disclosed a reception and research announcement. Regarding the development of large-scale models and future application scenarios in the field of genetic testing, Berry Gene stated that it has carefully laid out two core areas in the company's overall planning, committed to promoting innovative development in the field of genetic testing and providing more accurate and comprehensive medical services for doctors and users. The first major sector, the company is committed to building an intelligent disease interpretation platform by integrating massive genetic data and clinical information, providing powerful decision support for doctors. The second major sector is to upgrade the genetic counseling model and create a health management model, committed to enhancing users' health awareness and quality of life. The company believes that through the coordinated development of these two major sectors, it will be able to provide more comprehensive and accurate medical services for doctors and users, and promote innovation and progress in the field of genetic testing.

 

 

 

On February 16th, Lexin Medical announced that it had received research from 62 institutions including Tianfeng Securities, Penghua Fund, Haifutong Fund, Dacheng Fund, and Hongli Fund on February 14th. It is mentioned that there are many applications of large models, but the company always focuses on cardiovascular disease. The company's main products are focused on medical grade health monitoring products and intelligent wearable products. Currently, it has a multi-dimensional physical health monitoring product line, which can provide comprehensive equipment support for large-scale model applications. In addition, the company's existing home medical and health products have passed medical registration certification (including future wearable products that will also apply for medical device registration certification), ensuring the accuracy of product monitoring and providing more precise data support for the application of big models.

 

 

 

It is reported that as of now, more than 30 medical and health companies have announced the integration of DeepSeek, which may have a huge impact on the industry as AI accelerates its landing in the medical field. Domestic policies have also been promoting the development of "artificial intelligence+medicine". In 2024, China proposed the "Artificial Intelligence+" initiative, and in November of the same year, three departments researched and formulated the "Reference Guidelines for Artificial Intelligence Application Scenarios in the Health Industry", which detailed 84 application scenarios including medical imaging intelligent assisted diagnosis, clinical specialized disease intelligent assisted decision-making, and intelligent outpatient triage. By 2025, it is expected that more pharmaceutical companies will actively embrace AI technology.